drugset
drugset / Trial / NCT00304096

Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer

NCT00304096 ↗

Phase 1 Completed 12 enrolled University of Virginia National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and kill more tumor cells. PURPOSE: This phase I trial is studying the side effects of vaccine therapy in treating patients with stage III or stage IV breast cancer.

Timeline

Start
2005-12
Primary completion
2007-06
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine Vaccine — Subcutaneous

Indications

breast cancer